Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718861 · ClinicalTrials.gov registry record · Phase 3
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
A Phase 3 study of Post Menopausal Osteoporosis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT00718861 is a Phase 3 study of Post Menopausal Osteoporosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 190 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT00718861, a Phase 3 study of Post Menopausal Osteoporosis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zoledronic acid
Study Locations (20)
Buenos Aires
- Novartis Investigative Site - Buenos Aires
- Novartis Investigative Site - Caba
- Novartis Investigative Site - Quilmes
Victoria
- Novartis Investigative Site - Geelong
- Novartis Investigative Site - Parkville
Other
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Leuven
California
- Novartis Investigative Site - San Diego
Colorado
- Novartis Investigative Site - Lakewood
Georgia
- Novartis Investigative Site - Gainesville
Indiana
- Novartis Investigative Site - Indiamapolis
Maine
- Novartis Investigative Site - Bangor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2008-05 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00718861
The ClinicalTrials.gov registry entry for NCT00718861 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post Menopausal Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00718861 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Buenos Aires, Victoria, Other.
Frequently Asked Questions
What is clinical trial NCT00718861 about?
NCT00718861 is a clinical study titled "3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs". This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
What is the current status of trial NCT00718861?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2008-05. Estimated completion is 2013-04.
What conditions does trial NCT00718861 study?
This clinical trial studies the following conditions: Post Menopausal Osteoporosis.
What interventions are being tested in trial NCT00718861?
The interventions under investigation include: Placebo (DRUG), Zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00718861?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00718861 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Indiana, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Menopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.